Are acellular vaccines driving the rise of pertactin-deficient Bordetella pertussis

无细胞疫苗是否会导致缺乏百日咳博德特氏菌的增加

基本信息

  • 批准号:
    10364771
  • 负责人:
  • 金额:
    $ 18.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-03-04 至 2023-02-28
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Bordetella pertussis, the respiratory pathogen responsible for “whooping cough,” causes an estimated 24 million cases of vaccine-preventable illness per year, resulting in an excess of 200,000 deaths annually. Importantly, the incidence of whooping cough in nations with high vaccine coverage is on the rise and has been recognized by both the CDC and NIH as a priority (re)emerging infectious pathogen of high concern. The flawed immunity conferred by acellular pertussis vaccines has been highly implicated in the re-emergence of whooping cough. Although acellular vaccines are reasonably effective in preventing severe disease, resultant immunity quickly wanes, and does not effectively prevent asymptomatic colonization or transmission of B. pertussis from vaccinated hosts to susceptible newborns. Rather than killed or attenuated bacteria, these vaccines are composed of 3-5 immunogenic proteins, notably, pertactin, a bacterial autotransporter that is now disrupted or absent in 85% of circulating strains in the United States. Bacterial adaptation in response to vaccine-driven pressure is suspected to have selected for pertactin-deficient strains, which may enable the bacterium to evade host immunity directed against pertactin. The high prevalence of pertactin deficient strains in the United States is taken as confirmatory evidence, but there is little robust experimental evidence to support or refute this hypothesis. More importantly, without clear experimental evidence, there is no consensus on how to respond, leaving the CDC and NIH to launch workshops and panels to try to tackle and understand the problem and consider possible solutions. Excitingly, we have developed a novel mouse model of natural infection that allows us, for the first time, to directly address vaccine driven selection for the loss of vaccine antigens, and here present preliminary data measuring the reduction in colonization and bacterial shedding from the nares of pertactin-deficient Bordetella bronchiseptica, a close ancestral relative of B. pertussis that naturally infects mice. Application of this model in vaccinated mice has generated preliminary data indicating that pertactin-deficient strains have an advantage in colonization and shedding from vaccinated hosts in comparison with wildtype B. bronchiseptica. These data are consistent with the expectation that pertactin deficiency measurably reduces fitness in unvaccinated hosts but increases fitness in vaccinated hosts. Therefore, we intend to employ our innovative mouse model to thoroughly investigate the role and effect of pertactin deficiency using representative isogenic B. pertussis strains. Together these experiments will provide the first direct evidence to either support or refute the controversial explanation of vaccine-driven evolution of B. pertussis, and thereby inform very different responses to the observed rise in incidence of disease and prevalence of circulating pertactin-deficient strains in countries with wide vaccine coverage.
项目摘要 造成“百日咳”的呼吸道病原体Bordetella buttussis导致估计 每年有2400万例疫苗可预防疾病,导致超过200,000例死亡 重要的是。重要的是,在疫苗覆盖率高的国家中百日咳的事件在 CDC和NIH崛起并已被认为是优先(RE)新兴的感染性病原体 高度关注。 acelaculular百日咳疫苗赋予的有缺陷的免疫力已高度 在咳嗽的重新出现时实施。尽管大疫苗是合理的 有效预防严重疾病,导致的免疫力迅速减弱,并且没有有效的 预防疫苗接种宿主的百日咳无症状的定殖或传播到易感性 新生儿。这些疫苗不是杀死或减毒细菌,而是由3-5个免疫原性组成 蛋白质,尤其是肌肉蛋白,一种细菌自动转移蛋白,现在在85%中被破坏或不存在 在美国循环菌株。响应疫苗驱动的压力的细菌适应为 怀疑已选择去肌蛋白质缺陷菌株,这可能使细菌逃避 宿主免疫针对发生性交。联合伴奏毒素不足菌株的高流行率 国家被视为确认证据,但几乎没有强大的实验证据可以支持或 驳斥这一假设。更重要的是,如果没有明确的实验证据,就没有达成共识 如何做出响应,离开疾病预防控制中心和NIH进行研讨会和面板,以尝试解决和 了解问题并考虑可能的解决方案。令人兴奋的是,我们已经开发了一种新颖的鼠标 自然感染模型,这使我们首次可以直接解决疫苗驱动选择 对于疫苗抗原的丧失,此处介绍了测量降低的初步数据 从伴发色素缺乏的Bordetella支气管炎的鼻菌和细菌脱落,A 自然感染小鼠的百日咳B.百日咳的亲密亲戚。在此模型中应用 接种疫苗的小鼠已经产生了初步数据,表明缺乏性菌株具有 与Wildtype相比,接种宿主的定植和脱落的优势。 支气管肽。这些数据与期望痛觉缺乏的期望是一致的 降低了未接种宿主的健身,但增加了接种宿主的适应性。因此,我们打算 员工我们创新的鼠标模型,以彻底研究心肌蛋白质缺乏的作用和效果 使用代表百日咳B.百日咳菌株。这些实验将共同提供第一个 直接证据支持或反驳B.疫苗驱动的进化的有争议的解释。 百日咳,从而告知对观察到的事件增加和 疫苗覆盖范围广泛的国家中循环性心肌缺乏菌株的患病率。

项目成果

期刊论文数量(13)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Modeling Immune Evasion and Vaccine Limitations by Targeted Nasopharyngeal Bordetella pertussis Inoculation in Mice.
  • DOI:
    10.3201/eid2708.203566
  • 发表时间:
    2021-08
  • 期刊:
  • 影响因子:
    11.8
  • 作者:
    Soumana IH;Linz B;Dewan KK;Sarr D;Gestal MC;Howard LK;Caulfield AD;Rada B;Harvill ET
  • 通讯作者:
    Harvill ET
Probing Immune-Mediated Clearance of Acute Middle Ear Infection in Mice.
The Neonatal Immune System and Respiratory Pathogens.
  • DOI:
    10.3390/microorganisms11061597
  • 发表时间:
    2023-06-16
  • 期刊:
  • 影响因子:
    4.5
  • 作者:
    Sedney CJ;Harvill ET
  • 通讯作者:
    Harvill ET
Modeling the catarrhal stage of Bordetella pertussis upper respiratory tract infections in mice.
模拟小鼠百日咳博德特氏菌上呼吸道感染的卡他期。
  • DOI:
    10.1242/dmm.049266
  • 发表时间:
    2022-05-01
  • 期刊:
  • 影响因子:
    4.3
  • 作者:
    Soumana IH;Dewan KK;Linz B;Rivera I;Ma L;Howard LK;Caulfield AD;Sedney CJ;Blas-Machado U;Sebo P;Harvill ET
  • 通讯作者:
    Harvill ET
Evolution and Conservation of Bordetella Intracellular Survival in Eukaryotic Host Cells.
  • DOI:
    10.3389/fmicb.2020.557819
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    5.2
  • 作者:
    Rivera I;Linz B;Harvill ET
  • 通讯作者:
    Harvill ET
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eric T Harvill其他文献

Eric T Harvill的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eric T Harvill', 18)}}的其他基金

An air-liquid interface system to study Bordetella pertussis interactions with respiratory epithelia
研究百日咳博德特氏菌与呼吸道上皮细胞相互作用的气液界面系统
  • 批准号:
    10665943
  • 财政年份:
    2023
  • 资助金额:
    $ 18.88万
  • 项目类别:
Protection against Bordetella pertussis transmission conferred by established and novel vaccines
现有疫苗和新型疫苗可预防百日咳博德特氏菌传播
  • 批准号:
    10375566
  • 财政年份:
    2021
  • 资助金额:
    $ 18.88万
  • 项目类别:
Protection against Bordetella pertussis transmission conferred by established and novel vaccines
现有疫苗和新型疫苗可预防百日咳博德特氏菌传播
  • 批准号:
    10194677
  • 财政年份:
    2021
  • 资助金额:
    $ 18.88万
  • 项目类别:
12th International Symposium on Bordetella
第12届博德特氏菌国际研讨会
  • 批准号:
    9761709
  • 财政年份:
    2019
  • 资助金额:
    $ 18.88万
  • 项目类别:
12th International Bordetella Symposium
第十二届国际博德特氏菌研讨会
  • 批准号:
    9805872
  • 财政年份:
    2018
  • 资助金额:
    $ 18.88万
  • 项目类别:
In vivo vaccine-driven evolution in Bordetella pertussis
百日咳博德特氏菌体内疫苗驱动的进化
  • 批准号:
    8986495
  • 财政年份:
    2015
  • 资助金额:
    $ 18.88万
  • 项目类别:
Systematic evaluation of B. pertussis ACT’s role as a protective antigen
百日咳博德特氏菌 ACT 作为保护性抗原的作用的系统评估
  • 批准号:
    9056231
  • 财政年份:
    2015
  • 资助金额:
    $ 18.88万
  • 项目类别:
The Microbiota Pathogen Competition
微生物群病原体竞赛
  • 批准号:
    9291478
  • 财政年份:
    2015
  • 资助金额:
    $ 18.88万
  • 项目类别:
Bordetella sp. Versus Microbiota
博德特氏菌属
  • 批准号:
    8896095
  • 财政年份:
    2014
  • 资助金额:
    $ 18.88万
  • 项目类别:
Evolution of the Bordetellae from Commensals to Pathogens
博德特氏菌从共生菌到病原体的进化
  • 批准号:
    7886472
  • 财政年份:
    2009
  • 资助金额:
    $ 18.88万
  • 项目类别:

相似国自然基金

时空序列驱动的神经形态视觉目标识别算法研究
  • 批准号:
    61906126
  • 批准年份:
    2019
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
  • 批准号:
    41901325
  • 批准年份:
    2019
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
  • 批准号:
    61802133
  • 批准年份:
    2018
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
  • 批准号:
    61872252
  • 批准年份:
    2018
  • 资助金额:
    64.0 万元
  • 项目类别:
    面上项目
针对内存攻击对象的内存安全防御技术研究
  • 批准号:
    61802432
  • 批准年份:
    2018
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 18.88万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.88万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 18.88万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.88万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 18.88万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了